|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to amino acids 480-530 of human ADAR2|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.2|
|Contains||15mM sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:200|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody detects endogenous protein at a molecular weight of 82 kDa.
Purity is >95% by SDS-PAGE.
ADAR2, also designated adenosine deaminase, RNA-specific (RED1), RNA-editing enzyme 1, DRABA2, DRADA2, ADAR2 alpha-L1, ADAR2 alpha-L2 and ADAR2 alpha-L3, mediates RNA editing by destabilizing RNA through deamination of adenosine to inosine. ADAR2 is responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. It can modify its own pre-mRNA and generate new splice sites. Translocation of endogenous ADAR2 from the nucleolus to the nucleoplasm results in increased editing of endogenous ADAR2 substrates. Alternative splicing of this gene results in several transcript variants that may influence RNA editing. RNA editing involves the deamination of adenosines at specific sites, the result of which can be a change in the amino acid sequence of the protein so that it differs from that predicted by the sequence of the DNA.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.